1.Significantly Higher Percentage of Circulating CD27(high) Plasma Cells in Systemic Lupus Erythematosus Patients with Infection than with Disease Flare-Up.
Deng Ho YANG ; Deh Ming CHANG ; Jenn Haung LAI ; Fu Huang LIN ; Chen Hung CHEN
Yonsei Medical Journal 2010;51(6):924-931
PURPOSE: To distinguish lupus flare-up from infection in systemic lupus erythematosus (SLE), we analyze the expression of circulating CD27(high) plasma cells in SLE patients with and without infection, in comparison to non-SLE patients with infection. MATERIALS AND METHODS: The percentage of circulating CD27(high) plasma cells was measured by flow cytometry in the following four groups: 36 SLE patients without infection, 23 SLE patients with infection, eight non-SLE patients with infection, and 26 healthy controls. RESULTS: The frequency of CD27(high) plasma cells had a correlation with the SLE disease activity index (SLEDAI) (r = 0.866, p < 0.05), level of anti-dsDNA (r = 0.886, p < 0.05), C3 (r = - 0.392, p < 0.05), and C4 (r = - 0.337, p < 0.05) in SLE patients without infection, but there was no correlation with disease activity in SLE patients with infection. Among three groups in particular-SLE without infection, SLE with infection, and non-SLE with infection-the percentages of CD27(high) plasma cells were elevated. The percentage of CD27(high) plasma cells was higher in SLE patients with infection, when compared to SLE patients without infection. CONCLUSION: The percentage of CD27(high) plasma cells is a biomarker for disease activity of SLE without infection, under correlation with SLEDAI, anti-dsDNA, and C3 and C4 level. However, when the SLE patients have an infection, the percentage of CD27(high) plasma cells is not an adequate biomarker for the survey of disease activity. The percentage of CD27(high) plasma cells may serve as a potential parameter to distinguish a lupus flare-up from infection.
Adult
;
Antigens, CD27/*biosynthesis
;
Bacterial Infections/complications
;
Biological Markers/metabolism
;
Case-Control Studies
;
Female
;
Flow Cytometry/methods
;
Humans
;
Lupus Erythematosus, Systemic/*blood/immunology
;
Male
;
Plasma Cells/cytology/*immunology
;
Virus Diseases/complications
2.Immunophenotypic Characterization and Quantification of Neoplastic Bone Marrow Plasma Cells by Multiparametric Flow Cytometry and Its Clinical Significance in Korean Myeloma Patients.
Young Uk CHO ; Chan Jeoung PARK ; Seo Jin PARK ; Hyun Sook CHI ; Seongsoo JANG ; Sang Hyuk PARK ; Eul Ju SEO ; Dok Hyun YOON ; Jung Hee LEE ; Cheolwon SUH
Journal of Korean Medical Science 2013;28(4):542-549
Multiparametric flow cytometry (MFC) allows discrimination between normal and neoplastic plasma cells (NeoPCs) within the bone marrow plasma cell (BMPC) compartment. This study sought to characterize immunophenotypes and quantitate the proportion of NeoPCs in BMPCs to diagnose plasma cell myeoma (PCM) and evaluate the prognostic impact of this method. We analyzed the MFC data of the bone marrow aspirates of 76 patients with PCM and 33 patients with reactive plasmacytosis. MFC analysis was performed using three combinations: CD38/CD138/-/CD45; CD56/CD20/CD138/CD19; and CD27/CD28/CD138/CD117. The plasma cells of patients with reactive plasmacytosis demonstrated normal immunophenotypic patterns. Aberrant marker expression was observed in NeoPCs, with negative CD19 expression observed in 100% of cases, CD56+ in 73.7%, CD117+ in 15.2%, CD27- in 10.5%, CD20+ in 9.2%, and CD28+ in 1.3%. In PCM patients, more than 20% of NeoPCs/BMPCs were significantly associated with factors suggestive of poor clinical outcomes. Patients who were CD27- or CD56+/CD27-, demonstrated shorter overall survival than patients of other CD56/CD27 combinations. Our results support the clinical value of immunophenotyping and quantifying NeoPCs in PCM patients. This strategy could help to reveal poor prognostic categories and delineate surrogate markers for risk stratification in PCM patients.
Adult
;
Aged
;
Aged, 80 and over
;
Antigens, CD27/metabolism
;
Antigens, CD56/metabolism
;
Asian Continental Ancestry Group
;
Bone Marrow Cells/*cytology/metabolism
;
Female
;
Flow Cytometry
;
Humans
;
*Immunophenotyping
;
Kaplan-Meier Estimate
;
Male
;
Middle Aged
;
Multiple Myeloma/metabolism/mortality/*pathology
;
Neoplasm Staging
;
Neoplastic Stem Cells/*cytology/metabolism
;
Prognosis
;
Republic of Korea
;
Risk Factors